[
  {
    "ts": null,
    "headline": "Quest Diagnostics price target raised to $198 from $190 at BofA",
    "summary": "BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and Contract Research Organizations is “particularly negative” heading into earnings given that these companies “sit at the intersection of a number of policy changes from the Trump Administration,” including headwinds from NIH budget cuts and global tariffs, as well as broader macro concerns, especially aro",
    "url": "https://finnhub.io/api/news?id=6327aacb1803d1b164b8c76a0900c40cee5d8fae2cd131894a6569fe2b8e85ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744725943,
      "headline": "Quest Diagnostics price target raised to $198 from $190 at BofA",
      "id": 133922528,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and Contract Research Organizations is “particularly negative” heading into earnings given that these companies “sit at the intersection of a number of policy changes from the Trump Administration,” including headwinds from NIH budget cuts and global tariffs, as well as broader macro concerns, especially aro",
      "url": "https://finnhub.io/api/news?id=6327aacb1803d1b164b8c76a0900c40cee5d8fae2cd131894a6569fe2b8e85ce"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics (DGX) Earnings Expected to Grow: Should You Buy?",
    "summary": "Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=3e284ebe86a57fc835995a426b1e603feeb163873a4c665ceff89f9242eb30bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744725639,
      "headline": "Quest Diagnostics (DGX) Earnings Expected to Grow: Should You Buy?",
      "id": 133922529,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=3e284ebe86a57fc835995a426b1e603feeb163873a4c665ceff89f9242eb30bf"
    }
  },
  {
    "ts": null,
    "headline": "Here's How Quest Diagnostics is Placed Ahead of Q1 Earnings",
    "summary": "DGX's first-quarter 2025 performance is likely to have been supported by the ongoing utilization of its Advanced Diagnostics and benefits from acquisitions.",
    "url": "https://finnhub.io/api/news?id=3202b3242d1dfc0ca9d4192aed29112955eb67422715eeee944caa62d74b64f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744723680,
      "headline": "Here's How Quest Diagnostics is Placed Ahead of Q1 Earnings",
      "id": 133922530,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "DGX's first-quarter 2025 performance is likely to have been supported by the ongoing utilization of its Advanced Diagnostics and benefits from acquisitions.",
      "url": "https://finnhub.io/api/news?id=3202b3242d1dfc0ca9d4192aed29112955eb67422715eeee944caa62d74b64f1"
    }
  }
]